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Sciences and ChinesAbstract Prevention of cross contamination with active pharmaceutical ingredients is crucial and
requires special attention in pharmaceutical industries. Current method validation describes the
determination of Nabumetone (NAB) residue on a stainless steel surface using swab sampling with
a sensitive HPLC-DAD analysis. The acceptance limit was decided as 2 mg swab per 100 cm2.
Cotton swabs impregnated with extraction solution were used to determine residual drug content.
Recoveries were 90.88%, 91.42%, and 92. 21% with RSD ranging from 2.2% to 3.88% at three
concentration levels. Residual concentration was found to be linear in the range of 0.1–4.56 mg/mL,
when estimated using a Phenomenex Luna C18 (25 cm 5 mm 4.6 mm i.d.) column at 1.0 mL/min
ﬂow rate and 230 nm. The mobile phase consisted of a mixture of methanol:acetonitrile:water
(55:30:15, v/v/v). The LOD and LOQ for NAB were found to be 0.05 and 0.16 mg/mL, respectively.
The validated method was found to be simple, selective and sensitive for demonstration of cleaning
validation of NAB residues on a stainless steel surface.
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e Pharmaceutical Association.1. Introduction
Cleaning validation is an important analytical challenge for
pharmaceutical industries. It stems primarily as a part of
mandatory good manufacturing procedure protocols due to
the obvious cross contamination potential. Secondly, it
requires development of selective and sensitive methods for
quantitative estimation of residues over the surface of manu-
facturing equipment after cleaning procedure. It involveslsevier B.V. All rights reserved.
OO
Figure 1 Structural formula of NAB.
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facturing lane to demonstrate complete removal of residues.
Current regulatory norms do not establish acceptance limits
for residues, but let an analyst decide it on the basis of logical
criteria such as risk associated with the quality or safety of
ﬁnished product.
Generally the limit for maximum accepted residue of active
ingredient (maximum allowable carryover, MACO) is based
on mathematical formulae, therapeutic doses and toxicological
proﬁle, which is kept at a general limit of 10 mg/mL [1–4].
Several approaches to express acceptance limits have been
proposed in the published scientiﬁc work. One approach is to
compare visual limit of detection (VLOD) with pharmacology
based criteria, where not more than 1/1000th of the therapeu-
tic dose of active component should be carried over to the next
batch as residue; lower of the two is considered as the residual
acceptance criterion. Another approach involves estimating
the total amount of allowable residue present on production
line, which is termed as residual acceptance level (RAL).
Further, the concentration of residue present per unit equip-
ment surface area may be computed, which is termed as speciﬁc
residual cleaning level (SRCL) or limit per surface area (LSA).
Nabumetone (NAB) is chemically 4-(6-methoxy-2-naphtha-
lenyl)-2-butanone; it is an ester prodrug of a new generation of
effective and orally active angiotensin-II receptor antagonist
(Fig. 1). It blocks the vasoconstrictor and aldosterone-secret-
ing effects of angiotensin-II, one of the most important
regulators of blood pressure [5,6]. The determination of
NAB from tablet formulation has been carried out by high
performance liquid chromatography (HPLC), high perfor-
mance thin layer chromatography (HPTLC) and spectro-
photometry, alone or in combination. Several analytical
methods have been reported for their determination alone or
in combination with other drugs in different dosage forms,
biological ﬂuids and urine using different analytical techniques
[7–9]. Available literature revealed that no method related to
residual determination of NAB was reported so far; hence it
was found worthwhile to determine LSA of NAB and to carry
out the development and validation of the method in order to
ensure trace level estimation of residues and to demonstrate
efﬁciency of the cleaning procedure.2. Experimental
2.1. Reagent and chemicals
NAB reference standard (USP) was obtained from IPCA
Labs, Ratlam, Madhya Pradesh, India, as a gratis sample.
Nilitis (NAB, 500 mg) tablets were procured from the manu-
facturer. HPLC grade water was prepared by taking reverse
osmosis water and passing it through a Milli-Q System(Millipore, Milford, USA). Alpha Swab polyester on a
propylene handle-TX714A (ITW Tex wipe, USA) was used
for extraction recovery sampling. HPLC grade acetonitrile and
methanol were obtained from Merck, Germany. All other
chemicals used were of analytical grade.
2.2. Chromatographic system and conditions
The LC system consisted of a (Shimadzu LC 10AT VP)
gradient pump with a universal loop injector (Rheodyne
7725i) of 20 mL injection capacity, a photodiode array detector
(PDA), SPD-10 AVP and Phenomenex Luna C18 (25 cm 5
mm 4.6 mm i.d.) column at 1.0 mL/min ﬂow rate, using
20 mL injection volume controlled by a PC work station
equipped with the software CLASS-VP (software M-10,
version 1.6; Shimadzu. Tokyo, Japan). Column temperature
was ambient. The mobile phase consisted of a mixture of
methanol:acetonitrile:water (55:30:15, v/v/v). The mobile
phase solution was ﬁltered through a 0.45 mm membrane ﬁlter
(Millipore) and degassed prior to use. The extraction solution
consisted of 60 mL mobile phase solution, 20 mL methanol
and 20 mL water (50:20:30, v/v/v). All chromatographic
experiments were performed in the isocratic mode. UV
detection was performed at 230 nm. The method was validated
as per ICH guidelines. The statistical analysis was performed
using Microsoft Excel 2007.
2.3. Standard solution preparation
The stock solution of standard was prepared by accurately
weighing NAB reference standard and transferring to a 50 mL
volumetric ﬂask. 20 mL of methanol was added and the
content of ﬂask was sonicated for 30 min. The solution was
appropriately diluted with the mobile phase to get the ﬁnal
concentration of 0.020 mg/mL. A series of calibration stan-
dards were prepared by transferring appropriate aliquots of
standard NAB solutions to separate 100 mL volumetric ﬂasks
to get dilutions.
2.4. Sample solution preparation
10 cm 10 cm of a stainless steel surface, appropriately
cleaned and dried, was sprayed with 250 mL of standard stock
solution for the positive swab control at all concentration
levels, and the solvent was allowed to evaporate. The surface
was wiped using a wet cotton swab, soaked with extraction
solution (mobile phase:methanol:water; 60:20:20, v/v/v). The
swab was squeezed into the swab tube as per the procedure
mentioned in Section 2.5. The background control sample was
prepared from the extraction solvent. The negative swab
control was prepared similarly. Care was taken to avoid
contact of swab with the test surface. Subsequently, the tubes
were placed in an ultrasonic bath for 15 min and the solutions
were analyzed by HPLC-DAD.
2.5. Swab wipes sampling protocol
Rinse and swab are two sampling methods available to
demonstrate cleaning validation. The swab technique is a
technique preferred by United States Food and Drug Admin-
istration [1,10,11]. The swabbing process is a subjective
N. Dubey et al.480manual process that involves physical interaction between the
swab and the surface, and thus may vary from operator to
operator [12–15]. So, a standardized motion protocol is
required to establish reproducible recoveries. A patch of
4 4in2. swab was immersed in the extraction solution and
folded diagonally. The excess solution was squeezed to avoid
unnecessary dilution of the drug. The folded swab was kept
between the thumb and second ﬁnger, so that necessary force
may be applied over the surface through ﬁrst ﬁnger. The
surface was wiped horizontally, starting from outside towards
the center. The fresh surface was exposed and repeatedly
wiped to extract the maximum residue. Finally the swab was
secured in a closed and labeled container for estimation.Table 1 Linear regression data in the analysis of NAB.
Statistical parameter Values
Concentration range (mg/mL) 0.1–4.56
Regression equation y¼38782xþ33512
Coefﬁcient of determination r2¼0.996
Residual standard deviation 9373.253. Results and discussion
3.1. Acceptance limit calculation
Cleaning validation of production lane is one of the most
critically controlled tasks. Visual as well as analytical observa-
tions help to achieve the goal. Considering SRCL, VLOD,
MACO and stainless steel surface area of 10 cm 10 cm, the
calculated limit per surface area (LSA) was decided as 2 mg
swab per 100 cm2.
3.2. Optimization of chromatographic conditions
Best chromatographic conditions were achieved by optimizing the
wavelength for detection, mobile phase composition and ﬂow
rate. The mobile phase consisted of a mixture of 55 mL methanol,
30 mL acetonitrile, and 15 mL water (55:30:15, v/v/v). Chroma-
tographic conditions were optimized to achieve appropriate plate
numbers, peak symmetry, resolution and tailing factor. The
calibration curve showed good linearity for lower concentrations,
required for trace level estimations at 230 nm.
3.3. Optimization of sample treatment
Cotton swabs were spiked with different quantities of drug
and placed into tubes. The optimum conditions were achieved
with mobile phase:methanol:water (60:20:20, v/v/v) as the
extracting solvent and soniﬁcation time of 15 min.Figure 2 Chromatograms obtained from (A) a non-s3.4. Validation of the method
The main objective of this study was to develop an HPLC-
DAD method for estimation of residues collected by swabs,
without interference of impurities originating from the swabs,
plates and extraction media. The method was validated for
linearity, precision, limit of detection (LOD), limit of quantiﬁca-
tion (LOQ), accuracy, selectivity, and stability of analyte [15–17].3.4.1. System suitability
The average number of theoretical plates per column was
43400, the USP tailing factor o1.2 and the resolution 42.0.
Relative standard deviation (RSD) of the peak areas was
o2.0%.3.4.2. Speciﬁcity
The speciﬁcity of the method was checked by using standard,
samples, the background control sample, the negative swab
control, and a swabbed un-spiked stainless steel plate (Fig. 2),
and four standard solutions were subjected to stress condi-
tions, which involved storage under destructive conditions like
elevated temperature (75 1C), acid environment, basic envir-
onment and oxidative condition ( H2O2 for 24 h). Chromato-
graphic resolution of more than 1.5 was achieved for NAB
from unknown peaks.3.4.3. Linearity
Standard solutions were analyzed at six different concentra-
tion levels ranging from 0.1 to 4.56 mg/mL, with six determi-
nations at each level. Linearity was observed when mean
response area was plotted against concentration, using the
least square and regression method (Table 1).piked stainless steel and (B) the excipient mixture.
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The LOD and LOQ were determined on the basis of standard
deviation of the response (y-intercept) and the slope of the
calibration curve at low concentration levels according to ICH
guidelines [18–20]. The LOD and LOQ for NAB were found
to be 0.05 and 0.16 mg/mL, respectively.
3.4.5. Precision and accuracy
Recovery is the percentage of residual material that is actually
removed by the sampling technique. Concentration of the analyte
was compared with that of the spiked sample at three different
concentration levels, 6 replicates each (1.91, 3.18 and 4.56 mg/mL).
Observations are reported (Table 2) as relative standard deviation
(RSD) and the recovery (%). Observations demonstrate appro-
priateness of the method for the purpose of residue monitoring.
Six consecutive injections of standard solutions on two
different days by different analysts and different reagents were
performed to evaluate the inter-mediate precision of the
method and expressed as the RSD. The RSD was found to
be 2.24% and 3.88% for the ﬁrst and second days, respec-
tively. The observations indicate acceptable inter-mediate
precision for NAB solution.
3.4.6. Robustness
Robustness of the HPLC-DAD method was demonstrated by
evaluation of the effect of different chromatographic parameters
on the resolution and the concentration of NAB samplesTable 2 Precision and accuracy of the results obtained from swa
Conc. added
(mg/mL)
Conc. found
(mg/mL)
1.91 1.69
3.18 2.89
4.56 4.21
Table 3 Effect of different chromatographic parameters over me
No. Parameters Conc. (lg/mL) RSD (%)
1. Wavelength (nm)
230 0.832 0.69
232 0.835 0.14
234 0.832 0.11
236 0.832 0.83
238 0.834 1.05
2. Mobile phase compositiona
52:33:15 0.831 1.12
53:32:15 0.834 0.34
54:30:16 0.832 0.63
56:30:14 0.832 0.92
57:28:15 0.836 0.45
3. Flow rate (mL/min)
0.8 0.832 0.54
0.9 0.837 0.66
1.0 0.834 0.32
1.1 0.823 0.92
1.2 0.827 1.32
aMobile phase composition shown as methanol:acetonitrile:water, v/(Table 3). The ﬂow rate was varied from 0.5 mL/min to
1.5 mL/min. The concentration of methanol in the mobile was
varied from 52% to 58% and response was recorded at
23074 nm. Signiﬁcant differences were not observed in chroma-
tographic parameters.3.4.7. Sample and standard stability
The stabilities of NAB in the swab matrix and NAB standard
solution were tested by storing them at ambient temperature for
24 h. They were injected after 6 h, 12 h and 24 h against fresh
standard solutions. The stabilities of the standard NAB solution
(4.8 mg/mL) and sample solutions after 24 h showed 2.16%
difference in results. The stability of NAB in swab matrix showed
2.87% difference in results. Chromatography of both the samples
showed no additional peaks (Figs. 3 and 4).3.4.8. Filter evaluation
Samples and standard solutions of NAB were ﬁltered with
Millipore millex — HV-PVDF 0.45 mm and millex — PTFE-
0.45 mm, and compared with unﬁltered samples. The Millipore
millex — HV-PVDF 0.45 mm and millex — PTFE-0.45 mm
pore size syringe ﬁlters were qualiﬁed for use with ﬁlter
evaluation ratio 100.28% and 100.36% for NAB standard
solution with PVDF and PTFE ﬁlters, respectively. For
samples, the ﬁlter evaluation ratio was 100.28% and 101.13%
for PVDF and PTFE ﬁlters, respectively.bbed plates spiked with NAB.
95% conﬁdence
interval (%)
%Recovery
(RSD, n¼6)
88.26–91.54 90.8870.81
90.47–92.84 91.4271.40
90.54–92.89 92.2170.63
thod performance.
Tailing factor Resolution Plate count
1.18 2.56 3532
1.20 2.44 3545
1.20 2.56 3624
1.18 2.45 3580
1.20 2.56 3573
1.18 2.11 3360
1.23 2.46 3450
1.22 2.52 3521
1.18 2.52 3312
1.22 2.48 3543
1.20 2.50 3455
1.20 2.56 3461
1.20 2.50 3578
1.18 2.32 3343
1.18 2.21 3211
v/v.
Figure 3 Chromatograms obtained from (A) Nabumetone standard solution, 2 mg/mL, and (B) ratio chromatogram of Nabumetone
standard solution.
Figure 4 Chromatograms obtained from (A) Nabumetone sample solution, 5 mg/mL, with 3-dimension chromatogram and (B) ratio
chromatogram of Nabumetone sample solution.
Table 4 Estimation of NAB in actual swab samples
(100 cm2 swabbed area) from different sampling points on
production lane.
No. Sampling point Residual conc. (lg/mL)
1. Upper hopper BDL
2. Lower hopper BDL
3. Die 0.332
4. Punch 0.362
5. Lid gasket 0.324
N. Dubey et al.4823.5. Estimation of NAB in swab samples collected from
production lane
Various samples were collected from different sampling points
over the production lane. Samples were tested for residual
content of NAB. Partial data are shown in Table 4.4. Conclusion
A validated, selective and simple HPLC-DAD method was
developed for residual determination of NAB to demonstrate
HPLC-DAD method validation for the determination of Nabumetone residues 483cleaning validation on stainless steel surfaces of the production
lane. The method with appropriate swab wipe procedure was
found to be precise, accurate and linear. No interference from
swab solution was observed and samples were stable for 24 h.
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